Alterations of lipid metabolism in men with hypotestosteronemia
- PMID: 1794844
- DOI: 10.1055/s-2007-1003708
Alterations of lipid metabolism in men with hypotestosteronemia
Abstract
Studied relationship in serum concentration of testosterone and lipids in 35 men with a positive coronarographic finding and 30 sterile men, in comparison with a control group. From lipid parameters we determined serum concentration of cholesterol, triacylglycerols and apolipoprotein B, and lipid distribution in lipoprotein fractions. Serum testosterone concentration was found decreased in both the group as against the controls. As to lipid parameters, cholesterol concentration was depressed in the high-density lipoprotein (HDL) fraction of both the clinical groups. As increased apolipoprotein B level was seen in men with the positive coronarographic finding. The results point to a negative effect of lowered testosterone concentrations on lipid metabolism.
Similar articles
-
Lipid metabolism in young males with hypotestosteronaemia and oligospermia prior to, during, and after treatment.Int Urol Nephrol. 1991;23(1):69-75. doi: 10.1007/BF02549731. Int Urol Nephrol. 1991. PMID: 1938220
-
Concentration of lipid, apoprotein-B and testosterone in patients with coronarographic findings.Klin Wochenschr. 1985 Oct 15;63(20):1071-4. doi: 10.1007/BF01739675. Klin Wochenschr. 1985. PMID: 4068611
-
Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.Acta Obstet Gynecol Scand. 1994 Feb;73(2):136-43. doi: 10.3109/00016349409013416. Acta Obstet Gynecol Scand. 1994. PMID: 8116352 Clinical Trial.
-
Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.Contraception. 1998 Aug;58(2):83-91. doi: 10.1016/s0010-7824(98)00074-2. Contraception. 1998. PMID: 9773262 Clinical Trial.
-
The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men.J Clin Endocrinol Metab. 2002 Jan;87(1):136-43. doi: 10.1210/jcem.87.1.8172. J Clin Endocrinol Metab. 2002. PMID: 11788637 Clinical Trial.
Cited by
-
Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention?Drugs Aging. 2008;25(5):357-69. doi: 10.2165/00002512-200825050-00001. Drugs Aging. 2008. PMID: 18447401 Review.
-
The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action?Br J Pharmacol. 2003 Mar;138(5):733-44. doi: 10.1038/sj.bjp.0705141. Br J Pharmacol. 2003. PMID: 12642373 Free PMC article. Review. No abstract available.
-
Fasting blood glucose and lipid profile alterations following twelve-month androgen deprivation therapy in men with prostate cancer.ScientificWorldJournal. 2012;2012:696329. doi: 10.1100/2012/696329. Epub 2012 Oct 17. ScientificWorldJournal. 2012. PMID: 23125556 Free PMC article.
-
Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis.Cent European J Urol. 2021;74(4):484-490. doi: 10.5173/ceju.2021.0260. Epub 2021 Dec 6. Cent European J Urol. 2021. PMID: 35083066 Free PMC article. Review.
-
Effect of testosterone replacement treatment in testosterone deficiency syndrome patients with metabolic syndrome.Korean J Urol. 2011 Aug;52(8):566-71. doi: 10.4111/kju.2011.52.8.566. Epub 2011 Aug 22. Korean J Urol. 2011. PMID: 21927705 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials